Safety and efficacy of lomefloxacin and cefaclor in the treatment of skin and skin structure infections

dc.contributorAmaya-Tapia, G., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico; Andrade-Villanueva, J., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico; Flores-Gaxiola, A., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico; Aguirre-Avalos, G., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico; Morfin-Otero, R., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico; Esparza-Ahumada, S., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico; Rodriguez-Noriega, E., Infectious Diseases Division, Hospital Civil de Guadalajara, Instituto de Patologia Infecciosa y Experimental, 'Dr. Francisco Ruiz Sanchez', Universidad de Guadalajara, Jalisco, Mexico
dc.creatorAmaya-Tapia, G.
dc.creatorAndrade-Villanueva, J.
dc.creatorFlores-Gaxiola, A.
dc.creatorAguirre-Avalos, G.
dc.creatorMorfin-Otero, R.
dc.creatorEsparza-Ahumada, S.
dc.creatorRodriguez-Noriega, E.
dc.date.accessioned2015-11-19T18:56:32Z
dc.date.accessioned2023-07-03T22:05:13Z
dc.date.available2015-11-19T18:56:32Z
dc.date.available2023-07-03T22:05:13Z
dc.date.created2015-11-19T18:56:32Z
dc.date.issued1992
dc.identifierhttp://hdl.handle.net/20.500.12104/69683
dc.identifier10.1016/0924-8579(92)90028-P
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-0027085922&partnerID=40&md5=34efa24bad3ef38438ce69be048eec5a
dc.identifierhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=18611520
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7243916
dc.description.abstractThe purpose of this study was to compare the safety and efficacy of lomefloxacin with that of cefaclor in the treatment of adult secondary bacterial skin and skin structure infections. The study was conducted as a randomized, single-blind comparison. Eighty patients enrolled in the study, of which 74 were evaluable: 37 patients in the lomefloxacin group and 37 in the cefaclor group. Patients received either 400 mg of lomefloxacin orally once daily or 250 mg of cefaclor orally three times daily for 12 days. The most frequent pathogens isolated included Staphylococcus aureus, Streptococcus pyogenes, coagulase-negative staphylococci, and Escherichia coli. The clinical response was similar in both groups (89.1%). The bacteriologic eradication rate was 100% in the lomefloxacin group and 94.5% in the cefaclor group. Adverse events were minimal. Once-daily lomefloxacin is a safe and effective treatment for secondary bacterial skin and skin structure infections caused by susceptible pathogens. © 1992.
dc.relationInternational Journal of Antimicrobial Agents
dc.relation2
dc.relation1
dc.relation55
dc.relation60
dc.relationScopus
dc.relationMEDLINE
dc.titleSafety and efficacy of lomefloxacin and cefaclor in the treatment of skin and skin structure infections
dc.typeArticle


Este ítem pertenece a la siguiente institución